The Pharmaco-genetic & Brain Mechanisms Associated With Cannabis- Induced

Status Not yet recruiting

Clinical Trial Summary

There is growing evidence of high rates of substance use disorders among individuals with psychotic disorders especially in young people with predisposition for psychosis. There is some genetic evidence that carriers of the valine158 allele of the catechol-O-methyltransferase (COMT) gene had increased risk to exhibit psychotic symptoms and to develop schizophrenia if they used cannabis by the age of 18. It was also shown that carriers of the COMT val/val genotype were most sensitive to THC-induced psychotic experiences but this was conditional on pre-existing susceptibility to psychosis. The investigators propose to use brain-imaging and molecular genetics to investigate whether genetic factors may contribute to the THC-induced dopamine release and possibly to cannabis- induced psychosis.

Clinical Trial Description

Genetic association study will be performed in 100 young cannabis users (age 18-26 years) for genes that are related to the neurotransmitters dopamine (D2, DAT, COMT), GABA, glutamate and the cannabinoid receptor CB1. Out of this cohort, 24 male subjects without history of cannabis or drug-induced psychosis will undergo brain imaging procedure in order to measure THC-induced dopamine release using [11C] Raclopride in PET imaging. Carriers of high activity COMT158Val allele are expected to show higher meso-limbic DA release than carriers of low activity COMT 158Met homozygotes and after smoking a cigarette with THC which in turn are thought to underlie the risk for THC-induced psychotic symptoms. The aim of the present study is to evaluate the relationship between the COMT genotype and cannabis-induced meso-limbic dopamine release as measured by D2 occupancy. In addition, the association between predisposition to psychosis, age of onset of cannabis dependence, and genotype of COMT and other neurotransmitters-related genes will be evaluated. Such finding could provide novel pharmaco-genetic explanation for the psychogenic effects of cannabis in vulnerable individuals. ;

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01565174
Study type	Observational
Source	Hadassah Medical Organization
Contact	Aviv M Weinstein, Ph.D
Phone	972-2-6776705
Email	avivweinstein@yahoo.com
Status	Not yet recruiting
Phase	N/A
Start date	October 2012
Completion date	October 2014

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04929938` - Application of UP for Transdiagnostic Treatment of Emotional Disorders for UHR for Psychosis Patients	N/A
Recruiting	`NCT05863572` - Strengthening Care in Collaboration With People With Lived Experience of Psychosis in Uganda	N/A
Completed	`NCT04277585` - Improving Access to Early Psychosis Coordinated Specialty Care	N/A
Recruiting	`NCT06197048` - Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder	N/A
Completed	`NCT04284813` - Families With Substance Use and Psychosis: A Pilot Study	N/A
Terminated	`NCT04404712` - FAAH Availability in Psychiatric Disorders: A PET Study	Early Phase 1
Recruiting	`NCT05769933` - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Recruiting	`NCT04298450` - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention	N/A
Not yet recruiting	`NCT05558332` - Youth Nominated Support Team	N/A
Not yet recruiting	`NCT05358457` - Pilot Study to Evaluate the Effectiveness of Online Familiar Metacognitive Training (MCTf)	N/A
Not yet recruiting	`NCT03807388` - ReMindCare App for Patients From First Episode of Psychosis Unit.	N/A
Completed	`NCT02895269` - COllaborative Shared Care to IMprove Psychosis Outcome	N/A
Recruiting	`NCT02622048` - Understanding and Helping Families: Parents With Psychosis	N/A
Completed	`NCT02733575` - Compassion Focused Therapy for Distressing Experiences	N/A
Completed	`NCT02653729` - Cbt for Psychosis and Affect on Psychosis Symptoms	Phase 2
Completed	`NCT02531243` - Computer-Aided Learning for Managing Stress	N/A
Not yet recruiting	`NCT02244970` - Mindfulness RCT for Early Psychosis	N/A
Enrolling by invitation	`NCT01364818` - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment	N/A
Withdrawn	`NCT00786318` - Ziprasidone vs Standard Therapy for Agitated Patients in the ED	Phase 4
Recruiting	`NCT00722163` - A Randomized Controlled Trial of Individual Therapy for First Episode Psychosis	Phase 0

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Pharmaco-genetic and Brain Mechanisms Associated With Cannabis- Induced Psychosis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms